What is the recommended treatment and prophylaxis for respiratory syncytial virus (RSV) in infants, including supportive care, aerosolized ribavirin for high‑risk patients (premature ≤35 weeks, chronic lung disease of prematurity, congenital heart disease, immunodeficiency, severe neuromuscular disorders), and monoclonal antibody prophylaxis (palivizumab or nirsevimab)?

Treatment of Respiratory Syncytial Virus (RSV)

Supportive care is the only proven treatment for RSV infection in most patients, with no antiviral or pharmacologic therapies recommended for routine use. 1, 2

Core Treatment Principles

Supportive Care (Mainstay for All Patients)

The American Academy of Pediatrics emphasizes that supportive management is the cornerstone of RSV treatment, as no pharmacologic interventions have demonstrated meaningful impact on morbidity, mortality, or quality of life outcomes. 1, 2

Essential supportive measures include:

• Oxygen supplementation when oxygen saturation falls persistently below 90% in previously healthy infants 1, 2
• Hydration support through adequate fluid intake assessment, with intravenous or nasogastric fluids for infants unable to maintain oral intake 1
• Fever and pain management with acetaminophen or ibuprofen as needed 1
• Nasal saline irrigation for symptomatic relief of upper respiratory symptoms 1

What NOT to Use

Critical pitfall: Palivizumab has absolutely no therapeutic benefit for treating established RSV infection—it is only approved for prevention in high-risk infants and should never be used as treatment. 3, 1

The American Academy of Pediatrics explicitly recommends against routine use of:

• Bronchodilators (including albuterol)—randomized controlled trials show no consistent benefit, with at most 1 in 4 children having transient improvement of unclear clinical significance 2
• Corticosteroids—no benefit demonstrated in bronchiolitis management 1
• Ribavirin for routine use in children with bronchiolitis 1
• Antibacterial medications unless specific indications of bacterial co-infection exist 1

Special Populations Requiring Antiviral Therapy

Hematopoietic Stem Cell Transplant (HSCT) Recipients

For HSCT patients with RSV lower respiratory tract infection, aerosolized ribavirin is the primary treatment option, though evidence is based mainly on observational data. 1

Aerosolized ribavirin dosing:

• 2 g over 2 hours every 8 hours, OR 6 g continuously over 18 hours per day for 7-10 days 1
• Monitor for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function 1
• Implement environmental controls to protect pregnant healthcare workers from teratogenic exposure 1

Systemic ribavirin (oral or intravenous) alternative:

• Day 1: 600 mg loading dose, then 200 mg every 8 hours 1
• Day 2: 400 mg every 8 hours 1
• Day 3 onward: Increase to maximum 10 mg/kg every 8 hours 1
• Renal adjustment: For creatinine clearance 30-50 mL/min, maximum 200 mg every 8 hours 1
• Monitor for hemolysis, abnormal liver function tests, and declining renal function 1

Combination therapy for HSCT patients:

• Consider adding intravenous immunoglobulin (IVIG) or anti-RSV-enriched antibody preparations for allogeneic HSCT recipients with RSV lower respiratory tract disease 1

Other Severely Immunocompromised Patients

Ribavirin therapy may be considered for:

• Solid organ transplant recipients with severe RSV infection 1
• Patients with profound lymphopenia (<100 cells/mm³) at high risk for progression to lower respiratory tract disease 1
• Mechanically ventilated infants with documented severe RSV infection 1

Timing considerations:

• Defer conditioning therapy for patients with RSV respiratory tract infection planned for allogeneic HSCT 1
• Consider deferring chemotherapy for patients with RSV infection scheduled for hemato-oncological treatment 1

Prevention Strategies

Monoclonal Antibody Prophylaxis

Palivizumab eligibility (NOT treatment—prevention only):

The American Academy of Pediatrics recommends palivizumab prophylaxis for:

• Infants born before 29 weeks 0 days gestation who are younger than 12 months at the start of RSV season 3, 4
• Infants with chronic lung disease/bronchopulmonary dysplasia requiring medical therapy (supplemental oxygen, diuretics, or chronic corticosteroids) within 6 months of RSV season onset 3, 4
• Children ≤24 months old with hemodynamically significant congenital heart disease 3, 4
• Profoundly immunocompromised children younger than 24 months during RSV season (may be considered) 3

Palivizumab dosing:

• 15 mg/kg intramuscularly monthly throughout RSV season 4
• Maximum of 5 doses per season 4
• After cardiac bypass surgery, administer an additional post-operative dose due to 58% decrease in serum concentration 3, 4

Discontinue palivizumab if the infant experiences a breakthrough RSV hospitalization, as the likelihood of a second RSV hospitalization in the same season is <0.5%. 3

Palivizumab efficacy: Reduces RSV hospitalization by 45-55% in high-risk populations but has no measurable effect on mortality and minimal effect on subsequent wheezing. 1, 2

Universal Prevention Measures

The American Academy of Pediatrics recommends for all infants:

• Complete elimination of tobacco smoke exposure 1, 2
• Limiting exposure to crowds and group childcare during RSV season 2
• Keeping infants away from sick contacts 2
• Encouraging breastfeeding to potentially decrease risk of lower respiratory tract disease 1, 2
• Ensuring influenza vaccination for the infant (starting at 6 months) and all household contacts 2

Infection Control (Critical for Healthcare Settings)

Hand hygiene is the single most important measure to prevent RSV transmission—programs implementing strict hand hygiene and droplet precautions have decreased nosocomial RSV transmission by 39-50%. 2

Essential infection control measures:

• Hand decontamination before and after direct patient contact, after contact with objects near the patient, and after removing gloves 1, 2
• Alcohol-based rubs preferred if hands are not visibly soiled 1, 2
• Gowns for direct patient contact 1, 2
• Contact and droplet precautions for all RSV-positive patients 1
• Education of personnel and family members on hand sanitation protocols 1, 2
• Restrict healthcare personnel with upper respiratory infections from caring for high-risk patients 1

Hospitalization Criteria

Indications for hospital admission:

• Hypoxemia (SpO2 persistently <90%) 1, 2
• Signs of severe respiratory distress 2
• Inability to maintain adequate oral intake 2
• Underlying high-risk conditions (immunocompromised, significant heart disease, chronic lung disease) 1

ICU transfer criteria:

• Failure to maintain SaO2 >92% in FiO2 >60% 1
• Shock 1
• Severe respiratory distress with rising PaCO2 (>6.5 kPa) 1
• Development of apnea or persistent grunting 1

Common Clinical Pitfalls to Avoid

• Never use palivizumab to treat active RSV infection—it has zero therapeutic benefit and is only for prevention 3, 1
• Do not continue bronchodilators without documented objective improvement in respiratory rate, work of breathing, or oxygen saturation 2
• Avoid overuse of antibiotics when there is no evidence of bacterial co-infection 1
• Do not use ribavirin routinely in otherwise healthy children with bronchiolitis—reserve for severely immunocompromised patients only 1
• Inadequate infection control measures leading to nosocomial transmission—hand hygiene is paramount 1, 2